You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

Claims for Patent: 8,802,129

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,802,129

Title:	Methods for treating retinopathy with extended therapeutic effect
Abstract:	Methods for treating and preventing retinopathic conditions by administering a glucocorticoid to the vitreous chamber of a patient at risk of, or suffering from, the retinopathy.
Inventor(s):	Whitcup; Scott M. (Laguna Hill, CA), Weber; David A. (Danville, CA)
Assignee:	Allergan, Inc. (Irvine, CA)
Application Number:	13/946,294
Patent Claims:	1. A method for treating an ocular condition, the method comprising the steps of: a) inserting an implant into an ocular site of a patient with an ocular condition, the implant comprising an active agent and a carrier associated with the active agent; b) releasing substantially all of the active agent from the implant; c) obtaining an improvement in the ocular condition at a time when a therapeutic amount of the active agent is not present at the ocular site; and d) maintaining the improvement in the ocular condition for an extended period of time during which the therapeutic amount of the active agent is not present at the ocular site; wherein the carrier comprises a 30/10 w/w mixture of hydrophilic end PLGA and hydrophobic end PLGA, wherein the active agent is ranibizumab, wherein the implant is formed by an extrusion method, and wherein the ocular condition is macular degeneration. 2. The method of claim 1, wherein the ocular site is the vitreous of the eye. 3. The method of claim 1, wherein the total weight of the implant is between about 100 .mu.g and about 2 mg. 4. The method of claim 1, wherein the implant is loaded with about 100-300 .mu.g of the ranibizumab.

Details for Patent 8,802,129

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	06/30/2006	⤷ Try a Trial	2024-04-30
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	08/10/2012	⤷ Try a Trial	2024-04-30
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	10/13/2016	⤷ Try a Trial	2024-04-30
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	03/20/2018	⤷ Try a Trial	2024-04-30
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.